 Tamoxifen premenopausal patients metastatic breast cancer review antiestrogen tamoxifen hormonal therapy breast cancer drug antiproliferative effects estrogen receptor ER mechanisms cellular actions tumor inhibition Clinically tamoxifen premenopausal postmenopausal patients drug complex endocrine effects dependent treatment duration dose menopausal status target organ postmenopausal women tamoxifen serum estrogen levels low gonadotropin levels decrease contrast estrogen levels many premenopausal women gonadotropin concentrations unchanged Large systematic trials metastatic breast cancer tamoxifen recommended hormonal therapy postmenopausal women ER-positive tumors Tamoxifen active agent premenopausal metastatic disease response rates comparable oophorectomy Clinical experience tamoxifen age group limited Few premenopausal women phase II phase III trials randomized trials total patients oophorectomy tamoxifen therapeutic equivalence survival advantage treatment Many questions appropriate role tamoxifen premenopausal patients attractive toxicity profile favorable therapeutic alternative premenopausal women ER-positive metastatic breast cancer surgical radiation castration